Stop Waiting to Be Asked: What Operators Really Need From Their Revenue Cycle Partners
When revenue cycle partners wait to be asked, or rely on “tell us what you…
Stop Waiting to Be Asked: What Operators Really Need From Their Revenue Cycle Partners
When revenue cycle partners wait to be asked, or rely on “tell us what you need” as a default, they miss critical opportunities to deliver meaningful performance, support their client organizations, and ultimately serve patients better. In today’s healthcare environment, partnership requires anticipation, not reaction. The post Stop Waiting to Be Asked: What Operators Really…
How Tech-Enabled Independent Pharmacies Can Address America’s Medication Adherence Crisis
Today’s technology has the potential to empower independent pharmacies to offer adherence support at a greater scale — and healthcare engagements that overlook this touchpoint miss out. The post How Tech-Enabled Independent Pharmacies Can Address America’s Medication Adherence Crisis appeared first on MedCity News.
Women’s Health Is Central to the Future of Digital Health
Innovation in women’s health technology is about improving input data, refining performance criteria and ensuring design assumptions align with biological reality and real-world usage. When those fundamentals are in place, products are more accurate, more trustworthy and more likely to be adopted by clinicians and consumers alike. The post Women’s Health Is Central to the…
Personas mayores inmigrantes pierden la cobertura de Medicare a pesar de haberla pagado
OAKLAND, Calif. — Rosa María Carranza se inclinó para sostener la espalda de una niña de 3 años mientras la pequeña trepaba una roca en las colinas boscosas del noreste de Oakland. Vestida con ropa de senderismo y collares de cuentas, Carranza, de 67 años, se movía entre árboles y niños en una mañana soleada…
This Northern Cheyenne Doula Was About To Start Getting Paid — Then Medicaid Cuts Hit
LAME DEER, Mont. — Misty Pipe had about an hour before her shift began at the post office. She used that time to check in on a new mom who lives a few miles outside this town at the heart of the Northern Cheyenne Indian Reservation. A mom of seven, Pipe is a doula on…
Can I Opt Out of Having My Doctor Take Notes With AI?
LISTEN: AI scribes are changing medical care. Here’s what to know if the technology shows up at your next doctor’s appointment. Family physician Eric Boose has been using an artificial intelligence tool to get back to what he calls “old-fashioned medicine” — talking with patients face-to-face, without having to type into a computer at the…
Digital Health Startups Raised $4B in Q1: How Cash Is Flowing Amid Uncertainty
Digital health funding rebounded in the first quarter of 2026, reaching $4 billion across 110 deals, according to data from Rock Health. The surge was fueled mainly by megadeals, reflecting a market where investors are placing larger bets on fewer startups. The post Digital Health Startups Raised $4B in Q1: How Cash Is Flowing Amid…
CEO Building AI’s “Health Universe” Utterly Unperturbed By Rivals
“We spend a lot of time focused on building the experiences that we think are the future of healthcare, and we don’t spend a heck of a lot of time worrying about what other people are doing,” declares Dan Caron, founder and CEO of Health Universe. Here’s a Q&A with the leader of the Kleiner…
TPA Yuzu Health Aims to Revamp Health Benefits with $35M Boost
Yuzu’s $35 million round was led by General Catalyst and Chemistry, with participation from Anthropic’s Anthology Fund, Bain Future Back Ventures, Timeless Ventures, Lachy Groom and Neo. The post TPA Yuzu Health Aims to Revamp Health Benefits with $35M Boost appeared first on MedCity News.
Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug
Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease Prader-Willi syndrome. This blockbuster prospect complements Crenessity, a Neurocrine drug approved for treating a rare endocrine disorder called congenital adrenal hyperplasia. The post Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug appeared first on MedCity…
